Issuance of New Ordinary Shares and TVR

11 August 2023

Kanabo Group PLC

("Kanabo" or the "Company")

Issuance of New Ordinary Shares and Total Voting Rights

Following the Company's announcement on 23 May 2023, an application has been made for the admission of 2,000,000 ordinary shares issued to 4th Consulting LLC ("4LLC") at a price of 3.01 pence, and the shares are expected to be admitted on 15 August 2023, to the Standard List of the London Stock Exchange ("Admission").

Following Admission, for the purposes of the Financial Conduct Authority's Disclosure Guidance and Transparency Rules, Kanabo announces that it has 632,427,870 ordinary shares of 2.5p each in issue ("Ordinary Shares"), each share carrying the right to one vote. The figure of 632,427,870 should be used by shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the Financial Conduct Authority's Disclosure Guidance and Transparency Rules.

The Directors of the Company accept responsibility for the contents of this announcement.

For further information, please visit http://www.kanabogroup.com/ or contact the following:

Enquiries:

About Kanabo Group Plc

Kanabo Group Plc (LSE:KNB) is a healthtech company committed to revolutionising patient care through its innovative technology platform and disruptive product offerings. Since its inception in 2017, Kanabo has been focused on researching, developing, and commercialising regulated medicinal cannabis-derived formulations and therapeutic inhalation devices.

Kanabo's NHS-approved online telehealth platform, The GP Service, provides patients with video consultations, online prescriptions, and primary care services. The Company is a leader in its field, focusing on improving patient outcomes and providing more accessible healthcare experiences.

The Company's partially owned subsidiary, Kanabo Agritec Ltd, is a cultivation consultancy supporting cannabis businesses in developing new farms through infrastructural, research, and product guidance. These farms deliver high-quality raw materials for Kanabo's formulas and product line.

In March 2023, Kanabo successfully launched its Pain Clinic, Treat It, under the expert guidance of its technological and product expertise. Treat It initially focuses on chronic pain management using plant-based medicine and treatments that are currently unavailable through traditional channels.

At Kanabo Group Plc, we are dedicated to providing patients with the highest quality medical treatments and more accessible healthcare experiences.

Visit www.kanabogroup.com for more information.